Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Nova Eye Medical ( (AU:EYE) ) is now available.
Nova Eye Medical will host an investor webinar on 3 March 2026 at 11:30 am AEDT, led by managing director Tom Spurling, to discuss the company’s half-year financial results and operational performance. Shareholders and interested investors can register online and submit questions in advance or during the live Q&A, underscoring the company’s focus on investor engagement and transparency around its progress in the glaucoma treatment market.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
More about Nova Eye Medical
Nova Eye Medical Limited is an ophthalmic medical technology company that develops, manufactures and sells proprietary treatment technologies and devices for glaucoma. Its portfolio includes the iTrack Advance minimally invasive glaucoma surgical device for mild to moderate disease and the Molteno3 drainage device platform for severe glaucoma, with global distribution supported from sales headquarters and manufacturing sites in the U.S. and New Zealand.
Average Trading Volume: 465,106
Technical Sentiment Signal: Hold
Current Market Cap: A$45.57M
Find detailed analytics on EYE stock on TipRanks’ Stock Analysis page.